About IO Biotech
IO Biotech (NASDAQ:IOBT) specializes in pioneering new pathways for immunotherapy to combat cancer. The focus of the company centers on the development of disruptive immune-modulating anti-cancer therapies designed to empower the immune system to defeat cancer. An essential part of IO Biotech's portfolio involves its proprietary T-win® technology platform, aiming at identifying and developing novel immune-modulating compounds. Current projects are geared towards advancing these innovative treatments through clinical trials, targeting a range of cancer types with the ultimate objective of bringing breakthrough solutions to patients in need. IO Biotech's mission revolves around transforming cancer treatment by unlocking the power of the immune system, demonstrating a commitment to cutting-edge research and the development of therapies that offer hope for improved outcomes in cancer care.
Snapshot
Operations
Products and/or services of IO Biotech
- IO102-IO103, an immune-modulating cancer vaccine targeting IDO and PD-L1, aims to enhance the immune system's ability to fight cancer.
- Collaboration with Merck on evaluating IO102-IO103 in combination with Keytruda for various cancer treatments, focusing on enhancing immunotherapy effectiveness.
- Expansion of the clinical trial portfolio to include multiple phase 2 and phase 3 studies, exploring IO102-IO103 in different cancer indications and settings.
- Development of a pipeline of early-stage assets targeting novel immune-modulatory mechanisms, aimed at overcoming resistance to current therapies.
- Investment in proprietary technology platform for the discovery and development of novel immunotherapies that can be used alone or in combination with existing treatments.
- Engagement in strategic partnerships and collaborations to accelerate the development of its pipeline and bring innovative cancer treatments to patients faster.
IO Biotech executive team
- Dr. Mai-Britt Zocca Ph.D.Founder, President, CEO, Principal Financial Officer & Director
- Ms. Amy B. Sullivan M.B.A.Principal Accounting Officer & CFO
- Dr. Qasim Iftikhar Ahmad M.D.Chief Medical Officer
- Prof. Inge Marie Svane M.D., Ph.D.Founder & Clinical Advisor
- Prof. Mads Hald Andersen M.D., Ph.D.Co-Founder & Scientific Advisor
- Anders LjungqvistFounder
- Prof. Per Thor StratenFounder
- Mr. Eric Faulkner M.B.A.Chief Technical Officer
- Mr. Devin Whittemore Smith J.D.Secretary, General Counsel & Chief Compliance Officer
- Mr. Daniel G. Mannix Ph.D.Senior Vice President of Regulatory Affairs